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Abstract
Small molecule inhibitors of protein geranylgeranyltransferase-I (GGTase-I) provide a promising type of anticancer drugs.
Here, we first report the identification of a novel tetrahydropyridine scaffold compound, P61-E7, and define effects of this
compound on pancreatic cancer cells. P61-E7 was identified from a library of allenoate-derived compounds made through
phosphine-catalyzed annulation reactions. P61-E7 inhibits protein geranylgeranylation and blocks membrane association of
geranylgeranylated proteins. P61-E7 is effective at inhibiting both cell proliferation and cell cycle progression, and it induces
high p21
CIP1/WAF1 level in human cancer cells. P61-E7 also increases p27
Kip1 protein level and inhibits phosphorylation of
p27
Kip1 on Thr187. We also report that P61-E7 treatment of Panc-1 cells causes cell rounding, disrupts actin cytoskeleton
organization, abolishes focal adhesion assembly and inhibits anchorage independent growth. Because the cellular effects
observed pointed to the involvement of RhoA, a geranylgeranylated small GTPase protein shown to influence a number of
cellular processes including actin stress fiber organization, cell adhesion and cell proliferation, we have evaluated the
significance of the inhibition of RhoA geranylgeranylation on the cellular effects of inhibitors of GGTase-I (GGTIs). Stable
expression of farnesylated RhoA mutant (RhoA-F) results in partial resistance to the anti-proliferative effect of P61-E7 and
prevents induction of p21
CIP1/WAF1 and p27
Kip1 by P61-E7 in Panc-1 cells. Moreover, stable expression of RhoA-F rescues
Panc-1 cells from cell rounding and inhibition of focal adhesion formation caused by P61-E7. Taken together, these findings
suggest that P61-E7 is a promising GGTI compound and that RhoA is an important target of P61-E7 in Panc-1 pancreatic
cancer cells.
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Introduction
Proteins such as the Rho family G-proteins are posttranslation-
ally modified by the addition of a geranylgeranyl isoprenoid [1].
The isoprenoid modification is important for membrane associ-
ation and functions of these proteins. Recent studies have
highlighted the significance of protein geranylgeranylation in
human cancers. First, it has been shown that a number of
geranylgeranylated proteins play important roles in tumorigenesis
and metastasis [2–6]. Second, characterization of GGTase-I-
deficient cells showed that the inhibition of GGTase-I leads to
proliferation inhibition and accumulation of p21
CIP1/WAF1,
pointing to the significance of GGTase-I in cell proliferation and
cell cycle progression [7]. Furthermore, conditional knockout of
the b-subunit of GGTase-I results in the inhibition of lung tumor
growth and increased survival of mice expressing oncogenic K-ras
[7]. Thus, inhibition of protein geranylgeranylation is a promising
approach for developing anticancer drugs, and inhibitors of
GGTase-I (GGTIs) are currently undergoing preclinical studies.
The results obtained are consistent with the idea that GGTIs
disrupt oncogenic and tumor survival pathways, inhibit prolifer-
ation and anchorage-independent growth, and induce apoptosis
[8–12].
A variety of approaches were taken to develop GGTI
compounds. Peptidomimetic GGTI compounds were derived
from the peptide bearing the C-terminal CAAL (cysteine followed
by two aliphatic amino acids and the C-terminal residue is leucine
or phenylalanine) motif, a sequence recognized by GGTase-I
[11,13–16]. The first nonpeptidomimetic inhibitor, GGTI-DU40,
was identified via high-throughput screening of a compound
library [17]. More recently, quantitative structure-activity rela-
tionship (QSAR) models for GGTIs have been developed and
used to carry out virtual screen of more than 9 million
commercially available compounds. This resulted in the identifi-
cation of seven compounds with novel scaffolds [18]. Our
approach [19,20] was to construct a library of allenoate-derived
small molecules based on phosphine-catalyzed annulation reac-
tions that produce diverse compounds such as dihydropyrroles
[21,22], tetrahydropyridines [23–25], bicyclic succinimides, diox-
anylidenes [26], a-pyrones [27], dihydropyrones [28,29], and
cyclohexenes [30]. Initial GGTI compounds identified by
screening a 171-compound pilot library were then used to
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compounds enabled us to identify two types of novel GGTI
compounds: one group with a dihydropyrrole ring as its core
scaffold and the other group with a tetrahydropyridine ring as its
core scaffold [19,20]. In our previous study, we reported that
derivatization of a carboxylic acid emanating from the dihydro-
pyrrole ring of one of the GGTI compounds dramatically
improves their cellular activity [20]. The improved GGTI, P61-
A6, inhibits proliferation of a variety of human cancer cell lines,
and causes G1 cell cycle arrest and induction of p21
CIP1/WAF1
[20]. Our study with P61-A6 using a human pancreatic cancer
xenograft model in mice showed that the GGTI exhibited
prolonged blood circulation time and significant suppression of
tumor growth [12].
In this study, we focused on P3-E5, a GGTI compound with a
tetrahydropyridine ring [20], and modified it with an L-leucine
methylester to replace the free acid. This led to the synthesis of
GGTI P61-E7. Compound P61-E7 selectively inhibits protein
geranylgeranlyation in cells with higher potency than P61-A6 and
caused accumulation of both RhoA and RalA, which are known
substrates of GGTase-I, in the cytosolic fractions. Furthermore,
compared to P61-A6, P61-E7 exhibits improved potency to inhibit
both cell proliferation and cell cycle progression and inducing
p21
CIP1/WAF1 level. In addition, compound P61-E7 increases
p27
Kip1 level and inhibits phosphorylation of p27
Kip1 (T187). P61-
E7 also blocks anchorage-independent growth and disrupts cell
morphology of Panc-1.
We also examined the mechanism of action of P61-E7 in
pancreatic cancer cells. This is important because the cellular
effects observed pointed to the involvement of RhoA, a
geranylgeranylated small GTPase shown to mediate a number
of cellular processes such as actin stress fiber organization, cell
adhesion and cell proliferation, the significance of the inhibition
of RhoA geranylgeranylation on GGTI-mediated cellular effects
was evaluated. We showed that stable expression of farnesylated
RhoA mutant (RhoA-F) prevents induction of p21
CIP1/WAF1 and
p27
Kip1 by P61-E7 in Panc-1 and promotes partial resistance to
the anti-proliferative effect of the GGTI compound. Further-
more, stable expression of RhoA-F rescues Panc-1 cells from cell
rounding and inhibition of focal adhesion formation following
P61-E7 treatment. Taken together, our findings show that P61-
E7 provides a novel addition to the range of GGTI compounds
that are in development as anticancer drugs and that RhoA is an




The allenoate-derived compound library was synthesized as
described in our previous publications [19,20]. Briefly, GGTI
P61-E7 (Fig. 1A) was obtained by coupling P3-E5, a represen-
tative tetrahydropyridine carboxylic acid hit compound [20],
with L-leucine methyl ester, where the free acid is converted to a
L-leucine amido methyl ester (Fig. 1B). A 20 mM stock solution of
P61-E7 in dimethyl sulfoxide (DMSO) was kept at 220uCu n t i l
use. GGTI-298 was purchased from Sigma-Aldrich (St. Louis,
MO). Farnesyltransferase inhibitor (FTI) BMS-225975 [31] was
kindly provided by Dr. Veeraswamy Manne (Bristol-Myers
Squibb Co.).
Plasmids
We used 3xHA-RhoA pcDNA3.1 expression construct (UMR
cDNA Resource Center, Rolla, MO) as template DNA for site-
directed mutagenesis PCR driven by Pfu UltraH High-Fidelity
DNA Polymerase (Aligent Technologies, Wilmington, DE)
according to the manufacturer’s instructions with the following
primers: Farnesylated RhoA-CLVS was generated using F
(forward primer), 59AGAAAAAATCTGGTTGCCTTGTCT-
CGTGACTCGAGTCTAG-39, and R (reverse primer), 59-C-
TAGACTCGAGTCACGAGACAAGGCAACCAGATTTTTT-
CT-39.
Cell Lines and Cell Cultures
MiaPaCa-2 (ATCC, Rockville, MD), NIH3T3 (ATCC, Rock-
ville, MD) and Panc-1 (ATCC, Rockville, MD) cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM;
Cellgro, Herndon, VA). Jurkat (ATCC, Rockville, MD) cells were
maintained in RPMI 1640 medium (Cellgro, Herndon, VA). Both
media were supplemented with 10% (v/v) fetal bovine serum
(FBS; HyClone, Logan, UT) and 1% penicillin/1% streptomycin
stock solution (Invitrogen, Carlsbad, CA). All cells were cultured at
37uC in a humidified incubator at 5% CO2.
Figure 1. Structures of P61-A6 and P61-E7 and synthesis of P61-E7 from P3-E5. (A) Structures of compounds P61-A6 and P61-E7. (B)
Treatment of P3-E5 with L-leucine methyl ester, O-benzotriazole-N,N,N9,N9-tetramethyluronium hexafluorophosphate (HBTU) and N,N-diisopropy-
lethylamine (DIPEA) in dichloromethane provides P61-E7 in 95% isolated yield.
doi:10.1371/journal.pone.0026135.g001
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Panc-1 cells were grown to 80% confluency on 6-well plates and
transfected with Lipofectamine
TM 2000 (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. Briefly, 10 mlo f
Lipofectamine
TM 2000 reagent was diluted in 250 ml of OPTI-
MEM medium (Invitrogen, Carlsbad, CA) and was allowed to
equilibrate at room temperature for 5 min. 4.0 mg of plasmid
DNA per 250 ml of medium was suspended and allowed to
complex with the diluted Lipofectamine
TM 2000 for 20 min at
room temperature. Transfection complexes were added to cells in
serum-free DMEM without antibiotics and incubated at 37uC for
4–6 h. Medium was then changed and replaced with DMEM
containing 10% FBS, with penicillin-streptomycin, and the cells
were further incubated at 37uC for 48 h. To generate stable cell
lines, cells were passaged at 1:10, 1:20, and 1:50 dilutions into
selective medium containing 800 mg/ml of GeneticinH (G418
sulfate; Invitrogen, Carlsbad, CA). Cell clones were expanded into
mass culture, and expression of 3xHA-RhoA-GG and 3xHA-
RhoA-F was analyzed by Western blotting using antibodies against
the HA tag.
Subcellular Fractionation
NIH3T3 cells and Panc-1 cells stably expressing 3xHA-RhoA
were treated with DMSO, P61-A6, or P61-E7 for 48 h. Cells were
then washed and scraped into phosphate-buffered saline (PBS) and
centrifuged at 2,500 rpm for 5 min. Pellets were resuspended
(10 mM HEPES/KOH at pH 7.3, 10 mM KCl, 5 mM MgCl2,
0.5 mM DTT, and 16protease inhibitor mixture), incubated on
ice for 30 min and homogenized. Homogenates were centrifuged
at 10006g for 10 min to collect the cytosolic fractions (superna-
tant). The remaining pellets were then resuspended in buffer
containing 1% Triton X-100, 150 mM NaCl, 20 mM Tris-HCl at
pH 7.5, 1 mM EDTA, and 16 protease inhibitor mixture, and
centrifuged at 15, 000 rpm for 15 min to collect the membrane-
containing fractions (supernatant). Na
+/K
+ ATPase-a and
RhoGDI were used as markers for the membrane-containing
fractions and the cytosolic fractions, respectively.
Western Blotting
Cells were treated with DMSO, FTI BMS-225975, GGTI-298,
P61-A6 or P61-E7 for 48 h, harvested, and lysed in lysis buffer
(1% Triton X-100, 150 mM NaCl, 20 mM Tris-HCl at pH 7.5,
1 mM EDTA, and 16protease inhibitor mixture). Proteins were
then resolved by 12% or 12.5% SDS-PAGE and immunoblotted
with antibodies against unprenylated form of Rap1 (U-Rap1;
Santa Cruz Biotechnology, Inc.), p21
CIP1/WAF1 (Millipore, Teme-
cula, CA), p27
Kip1 (rabbit, Santa Cruz Biotechnology, Inc.),
phospho-p27
Kip1 (T187) (Invitrogen, Carlsbad, CA), HDJ-2
(NeoMarkers, Fremont, CA), RhoGDI (Santa Cruz Biotechnolo-
gy, Inc.), Na
+/K
+ATPase-a (Sigma), RalA (BD Bioscience), HA.11
(Covance) and Actin (Calbiochem). Detection was performed
using peroxidase-conjugated secondary antibodies (Biorad) and
Amersham ECL Plus
TM Western Blotting Detection Reagents (GE
Healthcare Life Sciences). Select bands were quantified using




Panc-1 cells were lysed in lysis buffer (1% Triton X-100,
150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 1 mM EDTA, and 16
protease inhibitor mixture). Lysates were incubated with p27
Kip1
antibodies (rabbit, Santa Cruz Biotechnology, Inc.) in 50% Protein
G/Sepharose beads slurry for 2 h at 4uC while rocking, then
washed four times with an excess of lysis buffer. Samples were then
boiled at 95uC for 10 min in 46 sodium dodecyl sulfate (SDS)-
sample buffer and analyzed by Western blotting as described
above.
Cell Proliferation Assays and Cell Cycle Analyses
Effects of GGTIs on cell proliferation were examined using the
CCK-8 cell counting kit (Dojindo Molecular Technologies,
Kumamoto, Japan) as described previously [20]. Briefly, cells
(3610
3) were seeded onto 96-well plates. The following day cells
were treated with the appropriate inhibitor as indicated in the
figure legends under low-serum conditions (0.5% FBS) for
72 hours. Cell Proliferation was calculated relative to the DMSO
control. The cell cycle profiles were analyzed by flow cytometry as
described previously [32].
Fluorescence Microscopy
To examine the effects of GGTI on actin cytoskeleton and focal
adhesion formation, cells were seeded on 4-well or 8-well chamber
slides. The following day, cells were treated as indicated in the
figure legends. Then cells were fixed in 3.7% formaldehyde-PBS
and permeabilized in 0.1% Trion X-100-PBS for actin fiber and
vinculin detection. Actin fibers were detected by incubation with
fluorescein isothiocyanate (FITC)-labeled phalloidin or tetra-
methyl rhodamine isothiocyanate (TRITC)-labeled phalloidin
(Sigma-Aldrich, St. Louis, MO) as indicated in figure legends.
Vinculin was detected with anti-vinculin antibodies (mouse,
Sigma-Aldrich, St. Louis, MO) and fluorescently conjugated
anti-mouse IgG antibody (Sigma-Aldrich, St. Louis, MO). Cell
images were visualized using a Zeiss Microscope (406magnifica-
tion). Images were captured using AxioVision software.
Anchorage Independent Growth Assay
Cells were seeded at a cell density of 1000 cells/well in duplicate
in 12-well culture dishes in 0.3% agar over a 0.5% bottom agar
layer. Various concentrations of P61-E7 or DMSO were
incubated in the top layer of cells. Cultures were re-fed and
treated with the GGTI or DMSO once weekly (14 days of
incubation in total). Colonies were stained with 1 mg/ml MTT
(tetrazolium salt) for 1 hour and scanned.
Results
Synthesis of GGTI P61-E7 by the Derivatization of the
Carboxyl Group on the Dihydropyrrole Ring of GGTI P3-
E5
We previously reported a novel small molecule GGTI
compound P61-A6 (Figure 1A) [20]. This compound was
identified by screening a pilot library of allenoate-derived
compounds made through phosphine catalysis for scaffolds that
can be used for further derivatization. The dihydropyrrole scaffold
identified was then derivatized to identify compounds with
improved potency and bioavailability. A particularly useful
observation was made concerning a modification of the carboxyl
group off of the dihydropyrrole ring that resulted in a dramatic
increase in cellular potency [19,20]. Along the way, we succeeded
in establishing a novel chemical library of .4,000 compounds
through phosphine-catalyzed annulations of resin-bound alleno-
ates.
The above initial study identified another scaffold that consists
of a tetrahydropyridine ring. P3-E5, a representative tetrahydro-
pyridine carboxylic acid compound, inhibits GGTase-I with IC50
value of 0.31 mM [20]. The inhibition was specific to GGTase-I, as
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S1). In this study, we derivatized the carboxyl group of P3-E5 to
generate compounds that exhibit increased cellular activity. From
a series of modified compounds, we identified P61-E7 that was
synthesized by coupling carboxylic acid of P3-E5 with L-leucine
methyl ester to yield an amido ester P61-E7 (Figure 1B). The
reaction carried out under the influence of O-benzotriazole-
N,N,N9,N9-tetramethyluronium hexafluorophosphate (HBTU) and
N,N-diisopropylethylamine (DIPEA) in chloromethane [33] was
efficient with 95% yield. P61-E7 demonstrated better cellular
GGTI activity than P3-E5; GI50 values with Jurkat cells were
3.5 mM and 20 mM for P61-E7 and P3-E5, respectively.
GGTI P61-E7 Exhibits Improved Ability to Inhibit
Geranylgeranylation in Cultured Mammalian Cells When
Compared to GGTI P61-A6
P61-E7 exhibits increased potency to inhibit protein geranylger-
anylation in cells (Figure 2A and 2B). In the first assay, we assessed
inhibition of protein geranylgeranylation by using an antibody that
specifically detects unprenylated form of Rap1 [34]. Rap1 is a Ras-
like GTPase that plays a role in cadherin-based cell adhesion [34],
and is a known substrate of GGTase-I. Panc-1 (Figure 2A) and
NIH3T3 cells (Figure 2B) were treated with DMSO, P61-A6, or
P61-E7 for 48 hours. Treatment with either P61-A6 or P61-E7 led
to the accumulation of unprenylated Rap1 in a dose-dependent
manner in both Panc-1 (Figure 2A) and NIH3T3 (Figure 2B) cells.
P61-E7 treatment resulted in the inhibition of protein geranylger-
anylation at much lower concentrations when compared to P61-A6
in both cell lines tested (Figure 2A and 2B). For example, at 5 mM,
P61-A6 increased the level of unprenylated Rap1 in Panc-1 cells by
2.6-fold when compared to DMSO, while 5 mM of P61-E7 caused
the level of unprenylated Rap1 in Panc-1 cells to increase by 12.5-
fold (Figure 2A). Likewise, at 5 mM, P61-A6 treatment did not
significantly changethelevel ofunprenyalted Rap1inNIH3T3 cells
compared to DMSO treatment, while 5 mM of P61-E7 resulted in
21-fold increase in unprenylated Rap1 level (Figure 2B). All these
findings reflected a significant improvement in the potency of P61-
E7 in inhibiting protein geranylgeranylation in cells.
Next, the specificity of P61-E7 was measured by determining its
ability to inhibit farnesylation of HDJ2 which is a cochaperone of
the heat-shock cognate protein 70 (hsc70) involved in protein
folding and traffic [35] and a known substrate of farnesyltransfer-
ase (FTase). NIH3T3 cells were treated with various concentra-
tions of P61-E7 (5, 10, and 20 mM) or BMS-225975, an FTase
inhibitor (FTI). While treatment with BMS-225975 slowed the
mobility of HDJ2 on SDS-polyacrylamide gel, no such mobility
shift was observed with P61-E7 treatment even when cells were
treated with 20 mM of P61-E7 (Figure 2C). These findings
indicated that P61-E7 selectively inhibits protein geranylgeranyla-
tion but not farnesylation in cells.
Treatment with P61-E7 results in increase of cytosolic
localization of geranylgeranylated proteins
Because prenylation is required for geranylgeranylated proteins
to be associated with cellular membranes, we assessed whether
P61-E7 treatment inhibits membrane association of proteins such
Figure 2. GGTI P61-E7 is a more potent inhibitor of geranylgeranylation compared with P61-A6. (A and B), P61-E7 or P61-A6 treatment
inhibits Rap1 geranylgeranylation in Panc-1 (A) and NIH3T3 (B) cells. Whole cell lysates from cells treated with DMSO, P61-A6, or P61-E7 for 48 h were
prepared and resolved on SDS-PAGE for immunoblotting analysis using antibodies against the unprenylated form of Rap1 (U-Rap1, upper panels, A
and B), or HDJ2 (loading control, lower panels, A and B). Data shown are representative of three independent experiments. The U-Rap1 and HDJ2
bands were quantified using ImageJ. Intensities of U-Rap1 bands were normalized to their respective loading control, and the results are given above
the images as fold change compared to the DMSO control. (C) Whole cell lysates from NIH3T3 cells treated with DMSO, P61-A6, P61-E7, or FTI BMS-
225975 for 48 h were prepared and resolved on SDS-PAGE for immunoblotting analysis using antibodies against the unprenylated form of Rap1 (U-
Rap1, upper panel), or HDJ2 (lower panel). Data shown are representative of three independent experiments.
doi:10.1371/journal.pone.0026135.g002
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(Figure 3A and 3B) and Panc-1 cells stably expressing 3xHA-RhoA
(Figure 3C and 3D) were treated with DMSO, P61-A6 or P61-E7,
and membrane and cytosolic fractions were prepared and
processed for SDS-PAGE followed by Western blotting. The
Na
+/K
+ ATPase-a membrane marker and the RhoGDI cytosolic
marker were used to confirm the separation of membrane-
containing and cytosolic fractions, respectively. As shown in
Figure 3, treatment with P61-E7 resulted in increases of RalA
(Figure 3A and 3B) and 3xHA-RhoA (Figure 3C and 3D) in the
cytosolic fractions of NIH3T3 cells and Panc-1cells stably
expressing 3xHA-RhoA, respectively, while their association with
the membrane fractions was decreased. Furthermore, at both
concentrations tested (5 and 10 mM), P61-E7 is more effective at
disrupting association of RalA (Figure 3A and 3B) and 3xHA-
RhoA (Figure 3Cand 3D) with the membrane fractions when
compared to P61-A6.
P61-E7 is More Effective at Inhibiting Cell Cycle
Progression, Inducing p21
CIP1/WAF1 Protein Level and
Blocking Cell Proliferation When Compared to P61-A6
As shown in Figure 4, treatment of Panc-1 (Figure 4A) and
MiaPaCa-2 (Figure 4B) cells with either P61-A6 or P61-E7 for 48 h
caused dose-dependent enrichment of G1 phase cells, whereas the
percentage of S phase cells decreased. Consistent with findings
discussed above, P61-E7 is more effective at inhibiting cell cycle
progression in both cell lines tested (Figure 4A and 4B). For
example, following treatment with P61-A6 (5 mM), the proportion
of Panc-1 cells in the G1 phase increased from 45.1%63.1%
(DMSO) to 48.4%61.4%, whereas the proportion of Panc-1cells in
the G1 phase increased to 62.7%62.2% following treatment with
P61-E7 (5 mM) (Figure 4A). Likewise, at 5 mM, P61-A6 treatment
causedanincreaseinproportionofMiaPaCa-2 cellsinthe G1 phase
by 2.6%61.3% in comparison to DMSO treatment, while
treatment of MiaPaCa-2 cells with 5 mM of P61-E7 increased the
proportion of cells in the G1 phase by 9.7%60.67% when
compared to DMSO treatment (Figure 4B).
The accumulation of G1 phase cells was associated with an
induction of proteins involved in the regulation of cell cycle. Both
P61-A6 and P61-E7 induced p21
CIP1/WAF1 expression level in
Panc-1 (Figure 4C) and NIH3T3 (data not shown) cells in a dose-
dependent manner. Similar to observations discussed above, P61-
E7 treatment resulted in a higher induction of p21
CIP1/WAF1 level
when compared to treatment with P61-A6 in both cell lines tested.
For example, at 20 mM, P61-A6 induced p21
CIP1/WAF1 level by
25.9-fold in comparison to DMSO treatment, while treatment
with 20 mM of P61-E7 induced p21
CIP1/WAF1 level by 61.2-fold
(Figure 4C).
Figure 3. P61-E7 causes an increase of cytosolic RalA and RhoA in comparison to P61-A6. NIH3T3 cells (A,B) and Panc-1 cells stably
expressing 3xHA-RhoA (C,D) were treated with DMSO, P61-A6, or P61-E7 for 48 h. Cytosolic and membrane fractions were prepared and processed
for SDS-PAGE, followed by Western blotting using antibodies against RalA (A, top panel), the HA tag (C, top panel), Na
+/K
+ ATPase-a (A and C, middle
panels) and RhoGDI (A and C, bottom panels). Data shown are representative of three independent experiments. The RalA (A, top panel), 3xHA-RhoA
(C, top panel), Na
+/K
+ ATPase-a (A and C, middle panels) and RhoGDI (A and C, bottom panels) bands were quantified using ImageJ. Intensities of
RalA and 3xHA-RhoA bands in the membrane or cytosolic fraction were normalized to their respective control for membrane or cytosolic fraction.
Subcellular localization of RalA (B) and 3xHA-RhoA (D) are represented as Membrane/Cytosolic ratio, relative to the DMSO controls (which were set at
a value of one).
doi:10.1371/journal.pone.0026135.g003
Novel Inhibitor of Geranylgeranyltransferase-I
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26135Besides inducing p21
CIP1/WAF1 expression, P61-E7 increased
p27
Kip1 protein level in Panc-1 cells (Figure S2A). Phosphorylation
of p27
Kip1 on Thr187 by cyclin E/CDK2 results in the association
of p27
Kip1 with SCF ubiquitin ligase, targeting it for degradation.
It has been shown that Cdk2 phosphorylates p27
Kip1 on Thr187
and promotes its nuclear degradation, and that the inhibition of
the phosphorylation results in nuclear accumulation of p27
Kip1
[36]. Therefore, we investigated whether P61-E7 inhibits phos-
phorylation of p27
Kip1 on Thr187 in Panc-1 cells. P61-E7
increased p27
Kip1 protein level in Panc-1 cells (Figure S2B and
S2C), while inhibiting the phosphorylation of p27
Kip1 on Thr187
(Figure S2B).
The abilities of P61-A6 and P61-E7 to inhibit proliferation of
Panc-1 cells under low-serum conditions (0.5%) were examined
and compared. Consistent with findings discussed above, P61-E7
is more effective at inhibiting cell proliferation (Figure 4D). For
example, at 1.25 mM, P61-A6 treatment inhibited proliferation by
9.72%611.5% in comparison to DMSO treatment, while
treatment with 1.25 mM of P61-E7 inhibited proliferation by
48.6%64.49%. The improved potency of P61-E7 to inhibit cell
proliferation when compared to P61-A6 reflects its increased
ability to inhibit protein geranylgeranylation inside the cells
(Figure 2).
P61-E7 Causes Actin Cytoskeleton Disorganization,
Abolishes Formation of Focal Adhesions, and Inhibits
Anchorage-Independent Growth of Panc-1 Cells
To further investigate cellular effects of P61-E7, we carried
o u te x p e r i m e n t su s i n gP a n c - 1c e l l s .F i r s t ,w ee x a m i n e dt h e
effects of P61-E7 on the cell morphology of Panc-1 cell.
Previous studies have shown that GGTase-I deficiency results
in disrupted actin cytoskeleton in fibroblasts [7], and that
GGTI treatment causes disorganization of actin cytoskeleton
and inhibits formation of vinculin-containing focal adhesions
[37]. Panc-1 cells were treated with DMSO or P61-E7 and the
Figure 4. P61-E7 exhibits improved potency to inhibit cell cycle progression and cell proliferation. Panc-1 (A) and MiaPaCa-2 (B) cells
were treated with DMSO, or the indicated concentrations of P61-E7 or P61-A6 for 48 h. Cell cycle profiles were monitored by flow cytometry. The
percentages of cells in each phase of the cell cycle are indicated by different shades. Data shown are averages 6 S.D. of three independent
experiments. (C) Panc-1 cells were treated with DMSO, or various concentrations of P61-E7 or P61-A6, and whole cell lysates were collected and
resolved on SDS-PAGE for immunoblotting using antibodies against p21
CIP1/WAF1. Results shown are representative of three independent
experiments. The p21
CIP1/WAF1 and RhoGDI (loading control) bands were quantified using ImageJ. Intensities of p21
CIP1/WAF1 bands were normalized
to their respective loading control, and the results are given above the images as fold change compared to the DMSO control. (D) Panc-1 cells were
treated with DMSO, P61-A6, or P61-E7 under low-serum conditions (0.5% FBS) for 72 hours. Cell Proliferation relative to the DMSO control (100%) is
plotted. Data shown are averages of two independent experiments, each in quadruplet.
doi:10.1371/journal.pone.0026135.g004
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As shown in Figure 5A, P61-E7 treatment caused disorganiza-
tion of actin cytoskeleton and significant cell rounding. We next
examined whether P61-E7 treatment had effects on focal
adhesion. This was examined by using antibody against
vinculin, one of the components of focal adhesion. As seen in
Figure 5A, the treatment with P61-E7 led to the disappearance
of vinculin punctate immunostaining at the periphery of Panc-1
cells. The staining became uniform throughout the cell. The
GGTI treatment had no effect on vinculin expression level
(data not shown). These results suggest that focal adhesion
assembly was inhibited by P61-E7.
In addition, a soft agar clonogenicity assay was used to measure
the effect of P61-E7 on the anchorage-independent growth of Panc-
1 cells. Treatment with increasing concentrations of P61-E7
impaired the anchorage-independent growth of Panc-1 cells in a
dose-dependent manner (Figure 5B and 5C). For examples, at
5 mM,P61-E7inhibited colonyformationby 42.9%64.1%, whileit
inhibited colony formation by 71.2%65.2% at 10 mM (Figure 5B).
Stable Expression of Farnesylated RhoA in Panc-1 Cells
Suppresses GGTI-induced Phenotypes
RhoA, a geranylgeranylated small GTPase, has been shown to
influence a number of cellular processes including actin stress fiber
Figure 5. Effects of P61-E7 on cell morphology and anchorage-independent growth of Panc-1. (A) Panc-1 cells were serum-starved in the
presence of DMSO or 5 mM P61-E7 for 24 h, followed by stimulation with 10% FBS in DMEM for 30 minutes. Actin fibers and focal adhesions were
visualized with TRITC-phalloidin and mouse anti-vinculin followed by FITC-conjugated anti-mouse antibody, respectively. Data are representative of
three independent experiments. (B) Cells were seeded at a cell density of 1000 cells/well in 12-well culture dishes in 0.3% agar over a 0.5% bottom
agar layer. DMSO or various concentrations of P61-E7 were included in the top layer of cells. Cultures were re-fed and treated with the GGTI or DMSO
once weekly (14 days of incubation in total). Colonies were stained with 1 mg/ml MTT for 1 hour and scanned. Shown are representative results from
three independent experiments, each in duplicate. (C) P61-E6 inhibits anchorage-independent growth of Panc-1. Growth in soft agar relative to the
DMSO control (100%) is plotted. Shown are the averages 6 S.D. of three independent experiments, each in duplicate.
doi:10.1371/journal.pone.0026135.g005
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cellular effects of P61-E7 observed pointed to the possible
involvement of RhoA in GGTI-mediated cellular effects. First,
the above results on the effects of GGTI to induce p21
CIP1/WAF1
are consistent with previous studies that have shown that small
GTPase protein RhoA (RhoA-GG) acts as a negative regulator of
p21
CIP1/WAF1 expression [38,39]. Effects of GGTI on actin
cytoskeleton also support the possibility that P61-E7 induces
cellular effects by blocking geranylgeranylation of RhoA, thereby
disrupting its subcellular localization and inhibiting its functions.
Indeed, results from our RhoA-GTP pull-down assay indicated
that P61-E7 inhibited activation of RhoA in a dose-dependent
manner (Figure S3). To assess the implication of RhoA in P61-E7
induced phenotypes, we constructed Panc-1 stable cell line
expressing farnesylated RhoA (RhoA-F). Using site-directed
mutagenesis, a RhoA-F mutant was generated by altering the
CAAX from CLVL to CLVS sequence to render RhoA a
substrate of farnesyltransferase. Previous studies showed that
farnesylated RhoA has the same subcellular localization as
geranylgeranylated RhoA, and that both RhoA prenyl isoforms
have similar effects on cell morphology, actin organization,
vinculin distribution, cell proliferation and p21
CIP1/WAF1 expres-
sion [40]. However, unlike wild-type RhoA (RhoA-GG), RhoA-F
is expected to be resistant to GGTI treatment. Therefore, if P61-
E7 does indeed increase p21
CIP1/WAF1 expression by blocking
geranylgeranylation of RhoA, stable expression of RhoA-F is
expected to overcome P61-E7’s effect on p21
CIP1/WAF1 expression.
We established populations of Panc-1 cells stably expressing
either 3xHA-tagged wild-type RhoA (3xHA-RhoA-GG) or
3xHA-RhoA mutant (3xHA-RhoA-F) as described in ‘‘Materials
and Methods,’’ and confirmed the prenylation of 3xHA-RhoA-
GG and 3xHA-RhoA-F in these stable cell lines by treating them
with DMSO, FTI BMS-225975, or GGTI-298 which is a
commercially available GGTI. Treatment with GGTI-298
inhibited protein geranylgeranylation as indicated by the
appearance of the unprenylated Rap1 band (Figure 6A, left
and right panels). Moreover, as expected, GGTI-298 treatment
slowed the mobility of 3xHA-RhoA-GG on SDS-PAGE,
indicating geranylgeranylation of 3xHA-RhoA-GG was inhibited
(Figure 6A, right panel). However, GGTI-298 did not change the
mobility of 3xHA-RhoA-F protein (Figure 6A, left panel).
Consistent with observations discussed above (Figure 2C), FTI
BMS-225975 inhibited farnesylation of HDJ2, a known substrate
of FTase, as shown by the appearance of the slower migrating
form of HDJ2 on SDS-PAGE (Figure 6A, left and right panels).
Furthermore, treatment with the FTI inhibited farnesylation of
3xHA-RhoA-F (Figure 6A, left panel) while it had no effect on
the mobility of 3xHA-RhoA-GG (Figure 6A, right panel). We
also checked the expression levels of RhoA-GG and RhoA-F in
the Panc-1 stable cell lines used in these experiments. As
indicated in Figure 6B, the levels of RhoA-GG and Rho-F were
similar in these stable cell lines.
To investigate whether stable expression of RhoA-F prevents
P61-E7 induction of p21
CIP1/WAF1, Panc-1 cells and Panc-1 cells
stably expressing either the wild-type RhoA (3xHA-RhoA-GG) or
mutant RhoA (3xHA-RhoA-F) were treated with DMSO or
various concentrations of P61-E7. Consistent with previous
observations, increases in p21
CIP1WAF1 protein levels were
observed in Panc-1 cell and Panc-1 cells stably expressing
3xHA-RhoA-GG (Figure 6C). On the contrary, induction of
p21
CIP1/WAF1 was not observed in Panc-1 cells stably expressing
3xHA-RhoA-F (Figure 6C). These results indicated that stable
expression of 3xHA-RhoA-F in Panc-1 prevented induction of
p21
CIP1/WAF1 by P61-E7.
We also found that the expression of RhoA-F prevented
induction of p27
Kip1 protein level by P61-E7. We treated Panc-1
cells and Panc-1 cells stably expressing either 3xHA-RhoA-GG or
3xHA-RhoA-F with DMSO or P61-E7. Consistent with previous
observations, increases in p27
Kip1 protein levels were observed in
Panc-1 cell and Panc-1 cells stably expressing 3xHA-RhoA-GG
(Figure 6D). On the other hand, P61-E7 did not increase p27
Kip1
protein level in Panc-1 cells stably expressing 3xHA-RhoA-F
(Figure 6D). These results showed that stable expression of 3xHA-
RhoA-F in Panc-1 inhibited the ability of P61-E7 to increase
p27
Kip1 level.
Next, we investigated whether stable expression of farnesylated
RhoA confers resistance to the antiproliferative effect of P61-E7.
Following treatment with DMSO or 5 mM of P61-E7, cell
proliferation of Panc-1 cells, Panc-1 cells stably expressing
3xHA-RhoA-GG, and 3 different clones of Panc-1 cells stably
expressing 3xHA-RhoA-F with different expression levels
(Figure 7B) was measured as described previously [20]. As shown
in Figure 7A, stable expression of 3xHA-RhoA-F promotes partial
resistance to the anti-proliferative effect of P61-E7 in a manner
that depends on its expression level in Panc-1 cells. With the
highest expression level of RhoA-F, Panc-1 (3xHA-RhoA-F) Clone
No. 8 showed the highest resistance to the anti-proliferative effect
of P61-E7 when compared with Panc-1 (3xHA-RhoA-F) Clone
No. 1 (lowest expression level) and Clone No. 4 (intermediate
expression level). These findings suggested that P61-E7 inhibition
of cell proliferation in Panc-1 cells is due, in part, to inhibition of
RhoA geranylgeranylation and hence its function.
We also examined whether cell morphology and actin
cytoskeleton changes induced by P61-E7 can be rescued by the
stable expression of 3xHA-RhoA-F in Panc-1 cells. As shown in
Figure 8, Panc-1 cells expressing 3xHA-RhoA-GG responded to
P61-E7, and morphological changes and actin cytoskeleton
disorganization were observed. In addition, vinculin staining
showed that focal adhesion formation was inhibited by the GGTI
treatment. In contrast, P61-E7 failed to induce morphological
changes and actin cytoskeleton changes in Panc-1 cells expressing
HA-RhoA-F. Furthermore, focal adhesions were still detected
even after P61-E7 treatment in this cell line. These results suggest
that stable expression of RhoA-F rescues Panc-1 cells from cell
rounding and inhibition of focal adhesion formation caused by
P61-E7.
Discussion
In this paper, we report successful identification of a novel
GGTI compound P61-E7 that has a tetrahydropyridine scaffold.
P61-E7 was derived by converting the free carboxylic acid moiety
on the tetrahydropyridine ring of a parent compound P3-E5 to L-
leucine amido methyl ester. P61-E7 exhibits increased potency to
inhibit protein geranylgeranylation compared to our previous
preclinical compound P61-A6 [12,20]. Inhibition of geranylger-
anylation was first shown by detecting the appearance of
unprenylated Rap1. In addition, P61-E7 was shown to be more
effective at inducing cytoplasmic accumulation of RalA and RhoA
in comparison to P61-A6.
The availability of a compound with increased potency enabled
us to define cellular consequences of inhibiting protein geranylger-
anylation. By using two compounds with different levels of potency
to inhibit geranylgeranylation (P61-E7 and P61-A6), we could look
for cellular effects that correlate with the inhibition of geranylger-
anylation. We examined the effects of P61-E7 on pancreatic
cancer cells Panc-1. We have shown that P61-E7 causes more
pronounced cell cycle block at the G1 phase compared with P61-
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CIP/WAF1 and p27
Kip1 protein levels.
(A) Effects of GGTI-298 and FTI BMS-225975 on prenylation of wild-type 3xHA-RhoA (RhoA-GG, geranylgeranylated) and 3x-HA-RhoA-F (farnesylated) mutant.
Panc-1 cells stably expressing 3xHA-RhoA-GG (right panels) or 3xHA-RhoA-F (left panels) were treated DMSO, BMS-225975, or GGTI-298 for 48 h. Whole cell
lysates were collected and analyzed for RhoA, Rap1, and HDJ2 processing by Western blotting. (B) Expression levels of 3xHA-RhoA-F and 3xHA-RhoA-GG in
Panc-1 stable cell lines used in this experiment were analyzed by immunoblotting using antibodies against the HA tag or actin (loading control). (C andD )
Panc-1 cells and Panc-1 cells stably expressing 3xHA-RhoA-GG or 3xHA-RhoA-F were treated with DMSO or P61-E7 for 48 h. Whole cell lysates were collected
and analyzed for protein levels of p21
CIP/WAF1 (C, top panel), p27
Kip1 (D, top panel), or Actin (C and D, bottom panels). Data shown are representative of three
independent experiments. The p21
CIP1/WAF1 (C, top panel), p27
Kip1 (D, top panel), and Actin (C and D, bottom panels) bands were quantified using ImageJ.
Protein Levels of p21
CIP1/WAF1 and p27
Kip1 are represented as relative level compared to the DMSO control.
doi:10.1371/journal.pone.0026135.g006
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CIP1/WAF1
induction in comparison to P61-A6. Furthermore, P61-E7
treatment resulted in a more pronounced inhibition of cellular
proliferation under low serum condition when compared to P61-
A6. The excellent correlation we observed between cellular effects
and increased potency to inhibit protein geranylgeranylation
supports the idea that the consequences of geranylgeranylation
inhibition include inhibition of cell cycle progression, induction of
p21
CIP1/WAF1 and inhibition of proliferation.
We also examined the mechanism of action of P61-E7 in this
paper, and our work suggests that RhoA is a major player in
GGTI-mediated effects on pancreatic cancer cells. We have shown
that P61-E7 induces p27
Kip1 level, suggesting that the treatment
with GGTI results in the increases of both p21
CIP1/WAF1 and
p27
Kip1 in Panc-1 cells. The mechanism of induction, however,
appears to differ between the two Cdk inhibitors. In the case of
p21
CIP1/WAF1, it appears that the induction is regulated at the
transcriptional level, as we have shown that GGTI induces
expression of p21-reporter construct [20]. On the other hand,
GGTI effect on p27
Kip1is associated with the inhibition of
phosphorylation of Thr187. Phosphorylation of p27
Kip1 (T187)
results in the association of p27
Kip1 with SCF ubiquitin ligase,
targeting p27
Kip1 for degradation [36]. Because P61-E7 inhibits
phosphorylation of p27
Kip1 (T187), it is possible that P61-E7
prevents degradation of p27
Kip1, causing accumulation of p27
Kip1
in the nucleus in Panc-1 cells.
The above results on the effects of GGTI on Cdk inhibitors raise
the possibility that the GGTI effects are mediated by RhoA. First,
it is known that RhoA acts as a negative regulator of p21
CIP1/WAF1
expression [38,39,41]. Second, RhoA is shown to be essential for
the degradation of p27
Kip1 [42–44] and that RhoA stimulates
p27
Kip1 degradation through its regulation of cyclin E/CDK2
activity [43]. Further support for the idea that many of the GGTI
effects we observed with Panc-1 cells are due to the inhibition of
RhoA function comes from additional effects of P61-E7 we
observed. We found that P61-E7 treatment results in cell
rounding, actin cytoskeleton disorganization and inhibition of
focal adhesion formation.
To evaluate the possibility that GGTI targets RhoA functions,
we have established stable cell lines of Panc-1 expressing a mutated
form of RhoA (RhoA-F). RhoA-F has the CAAL (CLVL) box
changed to CAAX (CLVS) so that the mutant protein is
farnesylated instead of being geranylgeranylated. Characterization
of these stable cell lines showed that the expression of RhoA-F
reversed the ability of GGTI to induce p21
CIP1/WAF1 and p27
Kip1.
Stable expression of RhoA-F rescued cells from cell rounding and
focal adhesion inhibition caused by P61-E7. Finally, we observed
partial rescue of GGTI-induced proliferation inhibition and this
rescue correlated with the expression levels of RhoA-F. These
results suggest that many of the GGTI effects are due to the
inhibition of RhoA functions. Our results on the rescue of
proliferation inhibition by the expression of RhoA-F is consistent
with the previous report that the expression of farnesylatable
RhoA and Cdc42 restores proliferation of GGTase-I deficient
fibroblasts expressing oncogenic K-Ras [7]. There are other
proteins implicated in the GGTI effects. One type of proteins is
Ral suggested to be involved in the GGTI effects of MiaPaca-2
pancreatic cancer cells [4]. It is possible that the Ral proteins are
involved in other aspects of GGTI effects such as tumor growth. In
addition, it has been suggested that Rac1and Rac3 proteins are
Figure 7. Stable expression of farnesylated RhoA promotes partial resistance to the anti-proliferative effect of P61-E7. (A) Stable
expression of farnesylated RhoA (3xHA-RhoA-F) partially prevents P61-E7 inhibition of proliferation in Panc-1 cells in a manner that depends on the
expression levels of 3xHA-RhoA-F. Panc-1 cells and Panc-1 stable cell lines expressing either wild-type 3xHA- RhoA-GG (clone no. 9) or RhoA-F mutant
(clone no. 1, 4, or 8) were treated with DMSO or various concentrations of P61-E7 for 72 h. Cell number was determined as described in ‘‘Materials
and Methods.’’ Cell proliferation relative to the DMSO control (100% value) is plotted. Data shown are averages 6 S.D. of three independent
experiments. (B) Protein levels of 3xHA-RhoA-GG (clone no. 9) and 3xHA-RhoA-F (clone no. 1, 4, or 8) in different clones of Panc-1 stable cell lines as
analyzed by immunoblotting using antibodies against the HA tag or actin (loading control).
doi:10.1371/journal.pone.0026135.g007
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is needed to express mutant forms of these proteins that can bypass
geranylgeranylation to gain complete understanding of the
mechanism of GGTI effects.
Supporting Information
Figure S1 Effects of P3-E5 on the enzymatic activities of
GGTase-I, RabGGTase, and FTase. GGTase-I and FTase




substrate proteins. FTase or GGTase-I (50 nM) was used to
initiate reactions containing 0.4 mM[
3H]farnesyl diphosphate
(FPP) (21.5 Ci/mmol, Perkin Elmer Life Sciences) or 0.5 mM
[
3H]geranylgeranyl diphosphate (GGPP) (23.0 Ci/mmol, Perkin
Elmer Life Sciences) and 2 mM maltose-binding protein-tagged
substrates (K-Ras4B for FTase and RhoA for GGTase-I) in 20 ml
of buffer containing 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2,
5 mM ZnCl2, 0.01% Triton X-100, and 1 mM dithiothreitol.
Inhibitors were added at the indicated concentrations. The final
DMSO concentration was 2.5% for all samples. Reactions were
carried out for 10 min at 30uC. The reaction mixture was spotted
onto a filter paper and treated with 10% trichloroacetic acid,
followed by ethanol and acetone washing. The filter was counted
using a scintillation counter. For RabGGTase assays, the reaction
contained the following components in 20 ml: 0.625 mlo f
[
3H]GGPP (0.7 mM), 25 nM RabGGTase, 0.6 mM REP-1,
0.6 mM purified Rab7 or Ypt1 protein, 40 mM HEPES
(pH 7.5), 150 mM NaCl, 5 mM dithiothreitol, 3 mM MgCl2,
and 0.3% CHAPS. Reactions were carried out for 20 min at
37uC, and the products were analyzed as described above for the
GGTase-I reaction. Data represent the mean 6 S.D. of two
measurements from two independent experiments.
(TIF)
Figure S2 Effects of P61-E7 on p27
Kip1 protein levels.
(A) Panc-1 cells were treated with DMSO or various concentra-
tions of P61-E7, and whole cell lysates were collected and resolved
on SDS-PAGE for immunoblotting using antibodies against
p27
Kip1. Results shown are representative of three independent
experiments. (B) and (C) Panc-1 cells were treated with DMSO or
P61-E7 (5 mM) for 48 h. Whole cell lysates were collected and
were immunoprecipitated (B) with anti-p27
Kip1 antibodies in 50%
Protein G/Sepharose beads slurry (negative control for immuno-
precipitation: whole cell lysates from untreated Panc-1 cells mixed
with slurry, without antibodies). (B) Immunoprecipitates were then
resolved on SDS-PAGE for immunoblot analysis using phospho-
27
Kip1(T187) antibodies (B, top panel) or p27
Kip1 antibodies (B,
bottom panel). Lanes: 1, DMSO-treated; 2, P61-E7-treated; 3, No
antibody control. (C) Remaining lysates (10 mg) from each sample
were resolved on SDS-PAGE for immunoblotting using antibodies
against p27
Kip1 (C, top panel) or actin (C, bottom panel) to
determine total p27
Kip1 level in each input used for immunopre-
cipitation. Results shown are representative of three independent
experiments. The RhoGDI, Actin, phospho-p27
Kip1 and total
p27
Kip1 bands were quantified using ImageJ, and the results are
given above the images as fold change compared to the DMSO
control.
(TIF)
Figure S3 P61-E7 inhibits RhoA activation in Panc-1
cells. Panc-1 cells were transfected with 3xHA-RhoA pcDNA
expression vector. Twenty-four hours after transfection, cells were
serum-starved in the presence of DMSO or P61-E7 for 24 h.
Then, cells were stimulated with 10% FBS in DMEM in the
Figure 8. Stable expression of farnesyalted RhoA rescues cells
from cell rounding and inhibition of focal adhesion assembly
caused by P61-E7. Panc-1 cells, Panc-1 cells stably expressing 3xHA-
RhoA-GG wild-type, and Panc-1 cells stably expressing 3xHA-RhoA-F
mutant were serum-starved in the presence of DMSO or 5 mM P61-E7
for 48 h, followed by stimulation with 10% FBS in DMEM. Actin fibers
and focal adhesions were visualized with FITC-phalloidin and mouse
anti-vinculin followed by TRITC-conjugated anti-mouse antibody,
respectively. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0026135.g008
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collected using Mg
2+-containing lysis buffer, and GTP-RhoA was
pulled down using GST-tagged Rhotekin-RBD protein beads
(Cytoskeleton) following the manufacturer’s instructions. Whole
cell lysates (inputs) and pull-down were resolved on SDS-PAGE
for immunoblotting analysis using HA.11 antibodies to detect total
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